Selection and Testing of Recombinant CAV 2- Rabies Vaccine for Oral Immunization of Wildlife

Award Information
Agency:
Department of Agriculture
Branch
n/a
Amount:
$79,700.00
Award Year:
2006
Program:
SBIR
Phase:
Phase I
Contract:
2006-33610-16801
Agency Tracking Number:
2006-00528
Solicitation Year:
n/a
Solicitation Topic Code:
n/a
Solicitation Number:
n/a
Small Business Information
Molecular Targeting Technologies, Inc.
882 S. Matlack Street Suite 105, West Chester, PA, 19382
Hubzone Owned:
N
Socially and Economically Disadvantaged:
N
Woman Owned:
N
Duns:
n/a
Principal Investigator:
Jeffrey Mattis
Sr. Vice President, Scientific Affairs
(610) 738-7938
jmattis@mtarget.com
Business Contact:
Koon Pak
President and CEO
(610) 738-7938
cpak@mtarget.com
Research Institution:
n/a
Abstract
Extensive worldwide reservoirs of rabies virus (RV) in wildlife and stray dogs continue to pose a serious risk of lethal infection of humans and cause a high economic burden. Immunization of wildlife and stray dogs with live vaccines is the only effective method to control and eventually eliminate rabies in carnivore species worldwide. In this application we propose to select canine adenovirus type-2 (CAV2) clones that optimally express the rabies virus (RV) G protein from previously engineered replication-competent CAV 2 - RVG constructs. These selected CAV 2-RVG viruses will be evaluated for safety and efficacy in laboratory animals as an initial proof of concept.

* information listed above is at the time of submission.

Agency Micro-sites

US Flag An Official Website of the United States Government